Cardiovascular Systems Inc. reported unaudited consolidated financial results for the second quarter and six months ended December 31, 2014. For the second-quarter, the company's revenues increased 38% to $44.7 million, from $32.3 million in the second quarter of fiscal 2014. Loss from operations was $5,252,000 compared to $7,495,000 last year. Net loss and comprehensive loss was $5,273,000 or $0.17 per basic and diluted share compared to $8,658,000 or $0.32 per basic and diluted share last year. Adjusted LBITDA was $1,316,000 compared to $4,627,000 last year. Excluding net coronary investments, adjusted EBITDA was positive for the quarter.

For the first six months, the company reported revenues of $86,086,000 compared to revenues of $62,103,000 for the same period a year ago. Loss from operations was $13,442,000 compared to $14,342,000 last year. Net loss and comprehensive loss was $13,497,000 or $0.43 per basic and diluted share compared to $15,950,000 or $0.61 per basic and diluted share last year. Adjusted LBITDA was $5,526,000 compared to $8,858,000 last year. Excluding net coronary investments, adjusted EBITDA was positive year to date.

For the third quarter ending March 31, 2015, the company anticipates revenue growth of 32% to 36% over the third quarter of fiscal 2014, to a range of $46.0 million to $47.7 million. Gross profit as a percentage of revenues similar to the second quarter of fiscal 2015. Net loss in the range of $10.0 million to $11.0 million, or loss per common share ranging from $0.32 to $0.35, assuming 31.6 million average shares outstanding.